JPH0567679B2 - - Google Patents
Info
- Publication number
- JPH0567679B2 JPH0567679B2 JP8784625A JP8462587A JPH0567679B2 JP H0567679 B2 JPH0567679 B2 JP H0567679B2 JP 8784625 A JP8784625 A JP 8784625A JP 8462587 A JP8462587 A JP 8462587A JP H0567679 B2 JPH0567679 B2 JP H0567679B2
- Authority
- JP
- Japan
- Prior art keywords
- oil
- acid
- albumin
- fatty
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003921 oil Substances 0.000 claims description 31
- 239000010685 fatty oil Substances 0.000 claims description 28
- 108010088751 Albumins Proteins 0.000 claims description 21
- 102000009027 Albumins Human genes 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 241000235789 Hyperoartia Species 0.000 claims description 11
- 229940092253 ovalbumin Drugs 0.000 claims description 8
- 108010058846 Ovalbumin Proteins 0.000 claims description 7
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 5
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 5
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 235000021313 oleic acid Nutrition 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- 229960002969 oleic acid Drugs 0.000 claims 1
- 235000019198 oils Nutrition 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000012085 test solution Substances 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- -1 fatty acid ester Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical class [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- 235000003441 saturated fatty acids Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000010775 animal oil Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 235000011118 potassium hydroxide Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 2
- 241000252203 Clupea harengus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 241001125048 Sardina Species 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 235000008524 evening primrose extract Nutrition 0.000 description 2
- 239000010475 evening primrose oil Substances 0.000 description 2
- 229940089020 evening primrose oil Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- RVRCFVVLDHTFFA-UHFFFAOYSA-N heptasodium;tungsten;nonatriacontahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[W].[W].[W].[W].[W].[W].[W].[W].[W].[W].[W] RVRCFVVLDHTFFA-UHFFFAOYSA-N 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- DSPXASHHKFVPCL-UHFFFAOYSA-N 1-isocyanocyclohexene Chemical compound [C-]#[N+]C1=CCCCC1 DSPXASHHKFVPCL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 241001609213 Carassius carassius Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 229920000887 Chrysolaminarin Polymers 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000542 fatty acid esters of ascorbic acid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940106134 krill oil Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
Description
産業上の利用分野
本発明は液状脂肪油−アルブミン複合体に関
し、さらに詳しくは液状脂肪油とアルブミンを結
合させた水不溶性の粉末状脂肪油−アルブミン複
合体に関する。
従来の技術
脂肪油は生物が栄養源として貯えている物質で
あり、全ての植物種子、動物の体内に含まれてい
る。従つてその種類は極めて多く、それぞれの性
質や用途が異なつている。
各脂肪油は、原料の違いにより植物油及び動物
油に分類でき、それらは多くの種類の脂肪酸を含
んでいる。ほとんどの動物は、正常な構造と機能
を維持するためにポリ不飽和脂肪酸を必要とし、
しかも飽和脂肪酸やモノ不飽和脂肪酸からポリ不
飽和脂肪酸を作る能力をもたないので、このよう
な不飽和物質を摂取する必要がある。また、魚
油、例えばヤツメウナギ油、イワシ油、ニシン油
などはビタミン類及び多種類の脂肪酸を含み、栄
養学上優れており栄養食用として有用されてい
る。エイコサペンタエン酸(EPA)またはドコ
サヘキサエン酸(DHA)は心筋硬塞、血栓性疾
患の予防及び治療のために用いられており、或い
は血清コレステロール低下作用を有することが知
られており軟カプセル剤として市販されている。
また、最近、炭素数が13乃至15及び21の飽和脂
肪酸及びオレイン酸、リノール酸、リノレン酸が
抗癌作用を有していることが見い出されている。
これらの脂肪油は酸化に対して不安定であるので
医薬品や食品に使用する時の製剤化が困難であつ
た。そのため種々の方法により軟カプセル剤とし
たり、懸濁液として利用されてきた。しかし、水
溶液では輸送、保存などに問題があり、安定な粉
末として提供されることが望まれていた。
前記した懸濁液として使用する方法として、脂
肪酸もしくはエステルを植物油、乳化剤及び水か
らなる脂肪輸液剤が知られている(特開昭60−
237017号公報参照)。
また、高度不飽和脂肪酸摂取時の不快な味を防
ぐためにエイコサペンタエン酸、ドコサヘキサエ
ン酸にレシチンを加える方法が知られている(特
開昭59−82070号公報参照)。
また、水に不溶性又は難溶性の薬物を可溶化す
るためにヒト血清アルブミンを加えることも知ら
れている(特開昭58−216126号公報参照)。しか
し、これらはいずれも溶液であり、液状脂肪油に
アルブミンを加え粉末状とすることは知られてい
なかつた。
発明が解決しようとする問題点
前記特開昭58−216126号公報で記載されている
ヒト血清アルブミンは、水不溶性又は難溶性の薬
物の水に対する溶解を容易にするのに対し、本願
発明により得られた複合体は水不溶性であり、か
つ、吸湿性がなく保存安定性にも優れている。
ほとんどの脂肪油は水不溶性であり、不飽和度
の高い脂肪酸を含むが、これが空気中の酸素によ
つて酸化分解し、悪臭物質を生じていた。そのた
め軟カプセル剤として服用してもゲツプと共に不
快臭が口中に残り服用するのに困難を要してい
た。
本発明は、脂肪油を粉末化するため、脂肪油と
沈澱を生ずるに充分な量のアルブミンを結合させ
ることにより水に不溶性の脂肪油−アルブミン複
合体を提供することにある。
問題点を解決するための手段
本発明は、液状脂肪油とアルブミンとを結合さ
せた粉末状脂肪油−アルブミン複合体に関する。
本発明において液状脂肪油とは、常温で液体の
ほか、加熱又は溶媒に溶解することにより液体と
することができるものであれば、いずれの脂肪、
脂肪酸又はこれらを含有する動物油又は植物油を
も挙げることができる。脂肪酸としては、飽和脂
肪酸及び不飽和脂肪酸が挙げられ、飽和脂肪酸と
しては、炭素数2乃至26の脂肪酸が挙げられ、特
にパルミチン酸、ステアリン酸、ラウリン酸及び
ミリスチン酸などが有利である。不飽和脂肪酸と
しては炭素数10乃至22の脂肪酸が挙げられ、特に
パルミトオレイン酸、オレイン酸、リノール酸、
リノレン酸、エイコサペンタエン酸、ドコサヘキ
サエン酸及びアラキドン酸が有利である。動物油
としては、イワシ油、ニシン油、タラ油、サメ
油、イカ油、鯨油、イルカ油、フナ油、コイ油、
ウナギ油、ヤツメウナギ油、オキアミ油、さなぎ
油及び牛脚油などが挙げられる。また植物油とし
ては、ゴマ油、オリーブ油、ナタネ油、大豆油、
綿実油、米油、トウモロコシ油、月見草油、紅花
油及びヒマシ油などが挙げられる。アルブミンと
しては、例えば卵白アルブミン、血清アルブミ
ン、プラクアルブミン、α−ラクトアルブミン、
ロイコシン、セフアリン及びレブメリンなどを挙
げることができるが、特に本発明により得られた
複合体を抗原性が問題となる医薬品の分野に適用
するにはヒト由来のアルブミンを用いるのが好ま
しい。
また、これら液状脂肪油にアスコルビン酸又は
その脂肪酸エステル及びビタミンEを加えること
により液状脂肪油−アルブミン複合体の安定性を
増すことができる。アスコルビン酸の脂肪酸エス
テルとしては、例えばビタミンCステアリン酸エ
ステル、パルミチン酸エステルを挙げることがで
きる。液状脂肪酸油に対するアスコルビン酸又は
その脂肪酸エステル及びビタミンEの添加割合は
特に限定されないが0.01〜1.0%が好ましい。ま
た、アスコルビン酸又は脂肪酸エステルとビタミ
ンEの割合は約1:1〜約1:10の範囲であれば
良い。
本発明の脂肪油−アルブミン複合体はまずアル
ブミンを水性溶液に溶解し、該溶解液に脂肪油を
加え両者を高速攪拌下(約5000〜30000rpm)に
接触させるだけで容易に製造することができる。
アスコルビン酸又はその脂肪酸エステル及びビ
タミンEを安定剤として加えるには、脂肪油に上
記安定剤を加えるのが好ましい。
この複合体を製造する時のアルブミン水溶液の
濃度は特に限定されないが、少なくとも1%
(W/V)好ましくは5乃至25%(W/V)の濃
度で使用することができる。脂肪油に対するアル
ブミンの使用割合も、反応により沈澱を生ずれば
臨界的ではなく広範に変え得るが、一般に、アル
ブミン100部にに対し脂肪油5乃至700部を加えた
割合で使用するのが好ましい。
水性溶液としては、アルブミンを変性させずに
溶解するものであればいずれのものをも使用する
ことができるが、水が最も好ましい。しかし、水
の一部をエタノール、プロピレングリコール、グ
リセリン等の水溶性溶剤をもつて置換することも
できる。
反応温度及び反応時間は臨界的でなく、使用す
るアルブミン及び脂肪油に応じて変え得るが、一
般には脂肪油が液体で、かつアルブミンが熱変性
を起こさない温度において約1乃至30時間両者を
攪拌下に反応させるのが有利である。
脂肪油とアルブミンは両者の加える割合には無
関係にほぼ100%反応し、両者の加える割合によ
り脂肪油に対しアルブミンが約5乃至250%結合
した沈澱が得られる。
かくして得られた沈澱は風乾、減圧乾燥、ドラ
ム乾燥、スプレー乾燥等の手段を用いて溶媒を除
去することにより目的とする粉末状の脂肪油−ア
ルブミン複合体を得ることができる。
以上に説明した本発明の脂肪油−アルブミン複
合体は吸湿性がなく、かつ水不溶性であり経時的
に安定であるという特徴を有している。そのた
め、得られた複合体を種々の形態に加工すること
が容易であり、例えば薬剤に通常使用される賦形
剤、結合剤、崩壊剤、滑沢剤などと共に錠剤やシ
ート状に加工することができる。また他の粉末に
対しても一様に混合することが可能となり食品、
化粧品、医薬、飼料などの分野で広く利用するこ
とができる。
本発明で得られた粉末状脂肪油−アルブミン複
合体は経時安定性に極めて優れている。後記実施
例1乃至5で製造した粉末状脂肪油−アルブミン
複合体を通気性を有する瓶に入れ、40℃、湿度75
%で30,60及び90日間保存した時の脂肪油の含有
率を重量の変化指標として測定した。
脂肪油の抽出及び定量方法
脂肪油−アルブミン複合体1乃至3gを200mlの
ナス型フラスコに精秤し、水2乃至6mlを加え、
さらに50乃至150mlのクロロホルム−メタノール
(2:1)溶液を加え、ジムロートをつけて窒素
ガス雰囲気下に、水浴上(60乃至65℃)で1乃至
2時間攪拌下加温した。冷却した後ろ過し、残分
を上記溶液25mlで2乃至3回洗浄し、洗液をろ液
と合わせた。ろ液と洗液とを窒素ガス雰囲気下、
粘調な液体となるまで減圧濃縮し、残分に石油エ
ーテル又はエーテルを50ml加えた。ワツトマン
IPSろ紙(商標)を用いてろ過後、ろ液を窒素ガ
ス雰囲気下、溶媒を留去しその重量(g)を測定
した。
その結果を下記第1表に示す。表中の数字は後
記実施例1乃至4に示した方法により得られた複
合体の脂肪油含有率を表す。
INDUSTRIAL APPLICATION FIELD The present invention relates to a liquid fatty oil-albumin complex, and more particularly to a water-insoluble powdered fatty oil-albumin complex in which liquid fatty oil and albumin are combined. BACKGROUND OF THE INVENTION Fatty oil is a substance stored by living organisms as a nutrient source, and is contained in all plant seeds and the bodies of animals. Therefore, there are many types, each with different properties and uses. Fatty oils can be classified into vegetable oils and animal oils depending on their raw materials, and they contain many types of fatty acids. Most animals require polyunsaturated fatty acids to maintain normal structure and function,
Moreover, they do not have the ability to make polyunsaturated fatty acids from saturated fatty acids and monounsaturated fatty acids, so they need to ingest such unsaturated substances. Furthermore, fish oils such as lamprey oil, sardine oil, and herring oil contain vitamins and various types of fatty acids, are nutritionally superior, and are useful as nutritional foods. Eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) is used for the prevention and treatment of myocardial infarction and thrombotic diseases, and is known to have serum cholesterol-lowering effects and is commercially available as soft capsules. has been done. Furthermore, it has recently been discovered that saturated fatty acids having 13 to 15 and 21 carbon atoms, oleic acid, linoleic acid, and linolenic acid have anticancer effects.
Since these fatty oils are unstable to oxidation, it has been difficult to formulate them for use in medicines and foods. Therefore, it has been used in the form of soft capsules or suspensions using various methods. However, aqueous solutions pose problems in transportation, storage, etc., and it has been desired to provide them as stable powders. As a method of using the above-mentioned suspension, a fat infusion preparation consisting of a fatty acid or ester, vegetable oil, an emulsifier, and water is known (Japanese Patent Application Laid-Open No. 1989-1999).
(Refer to Publication No. 237017). Furthermore, a method is known in which lecithin is added to eicosapentaenoic acid and docosahexaenoic acid in order to prevent unpleasant taste when ingesting highly unsaturated fatty acids (see Japanese Patent Application Laid-open No. 82070/1983). It is also known to add human serum albumin to solubilize drugs that are insoluble or poorly soluble in water (see Japanese Patent Application Laid-open No. 216126/1983). However, these are all solutions, and it has not been known to add albumin to liquid fatty oil and make it into a powder. Problems to be Solved by the Invention Human serum albumin described in the above-mentioned Japanese Patent Application Laid-Open No. 58-216126 facilitates the dissolution of water-insoluble or sparingly soluble drugs in water, whereas The resulting composite is water-insoluble, non-hygroscopic and has excellent storage stability. Most fatty oils are water-insoluble and contain highly unsaturated fatty acids, which are oxidized and decomposed by oxygen in the air, producing malodorous substances. Therefore, even when taken as a soft capsule, an unpleasant odor remains in the mouth along with burp, making it difficult to take. The present invention is to provide a water-insoluble fatty oil-albumin complex by combining a fatty oil with a sufficient amount of albumin to form a precipitate in order to powder the fatty oil. Means for Solving the Problems The present invention relates to a powdered fatty oil-albumin complex in which liquid fatty oil and albumin are combined. In the present invention, liquid fatty oil refers to any fat that is liquid at room temperature or that can be made liquid by heating or dissolving in a solvent.
Mention may also be made of fatty acids or animal or vegetable oils containing them. Examples of fatty acids include saturated fatty acids and unsaturated fatty acids. Examples of saturated fatty acids include fatty acids having 2 to 26 carbon atoms, with palmitic acid, stearic acid, lauric acid and myristic acid being particularly advantageous. Examples of unsaturated fatty acids include fatty acids having 10 to 22 carbon atoms, especially palmitooleic acid, oleic acid, linoleic acid,
Preference is given to linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid. Animal oils include sardine oil, herring oil, cod oil, shark oil, squid oil, whale oil, dolphin oil, crucian carp oil, carp oil,
Examples include eel oil, lamprey oil, krill oil, pupa oil and ox leg oil. Vegetable oils include sesame oil, olive oil, rapeseed oil, soybean oil,
Examples include cottonseed oil, rice oil, corn oil, evening primrose oil, safflower oil and castor oil. Examples of albumin include ovalbumin, serum albumin, plaque albumin, α-lactalbumin,
Examples include leucosin, cephalin, and levumelin, but it is preferable to use human-derived albumin, especially when the complex obtained by the present invention is applied to the pharmaceutical field where antigenicity is a problem. Further, by adding ascorbic acid or its fatty acid ester and vitamin E to these liquid fatty oils, the stability of the liquid fatty oil-albumin complex can be increased. Examples of fatty acid esters of ascorbic acid include vitamin C stearate and palmitate. The addition ratio of ascorbic acid or its fatty acid ester and vitamin E to the liquid fatty acid oil is not particularly limited, but is preferably 0.01 to 1.0%. Further, the ratio of ascorbic acid or fatty acid ester to vitamin E may be in the range of about 1:1 to about 1:10. The fatty oil-albumin complex of the present invention can be easily produced by first dissolving albumin in an aqueous solution, adding fatty oil to the solution, and bringing the two into contact with each other under high-speed stirring (approximately 5,000 to 30,000 rpm). . In order to add ascorbic acid or its fatty acid ester and vitamin E as a stabilizer, it is preferable to add the above-mentioned stabilizers to the fatty oil. The concentration of albumin aqueous solution when producing this complex is not particularly limited, but is at least 1%
(W/V) It can be used preferably at a concentration of 5 to 25% (W/V). The ratio of albumin to fatty oil is not critical and can be varied over a wide range as long as precipitation occurs during the reaction, but it is generally preferred to use a ratio of 5 to 700 parts of fatty oil to 100 parts of albumin. . Any aqueous solution can be used as long as it dissolves albumin without denaturing it, but water is most preferred. However, part of the water can also be replaced with a water-soluble solvent such as ethanol, propylene glycol, glycerin, etc. The reaction temperature and reaction time are not critical and can be varied depending on the albumin and fatty oil used, but generally both are stirred for about 1 to 30 hours at a temperature where the fatty oil is liquid and the albumin is not thermally denatured. It is advantageous to react below. The fatty oil and albumin react almost 100% regardless of the ratio of the two added, and depending on the ratio of the two added, a precipitate in which about 5 to 250% albumin is bound to the fatty oil can be obtained. The desired powdered fatty oil-albumin complex can be obtained by removing the solvent from the thus obtained precipitate using means such as air drying, vacuum drying, drum drying, spray drying, etc. The fatty oil-albumin complex of the present invention described above has the characteristics of not being hygroscopic, being water-insoluble, and being stable over time. Therefore, the obtained complex can be easily processed into various forms, such as tablets and sheets together with excipients, binders, disintegrants, lubricants, etc. commonly used in pharmaceuticals. I can do it. It is also possible to uniformly mix other powders into foods,
It can be widely used in fields such as cosmetics, medicine, and feed. The powdered fatty oil-albumin complex obtained by the present invention has extremely excellent stability over time. Powdered fatty oil-albumin complexes prepared in Examples 1 to 5 below were placed in an air-permeable bottle and heated at 40°C and humidity at 75°C.
The fatty oil content was measured as a weight change index when stored for 30, 60, and 90 days. Fatty oil extraction and quantitative method: Accurately weigh 1 to 3 g of the fatty oil-albumin complex into a 200 ml eggplant-shaped flask, add 2 to 6 ml of water,
Further, 50 to 150 ml of a chloroform-methanol (2:1) solution was added, and the mixture was heated with stirring on a water bath (60 to 65°C) for 1 to 2 hours under a nitrogen gas atmosphere with a Dimroth attached. After cooling, it was filtered, and the residue was washed 2 to 3 times with 25 ml of the above solution, and the washings were combined with the filtrate. The filtrate and washing liquid were heated under a nitrogen gas atmosphere.
It was concentrated under reduced pressure until it became a viscous liquid, and 50 ml of petroleum ether or ether was added to the residue. whatsman
After filtration using IPS filter paper (trademark), the solvent was distilled off from the filtrate under a nitrogen gas atmosphere, and its weight (g) was measured. The results are shown in Table 1 below. The numbers in the table represent the fatty oil content of the composites obtained by the methods shown in Examples 1 to 4 below.
【表】
さらに、本発明で得られた粉末状脂肪油−アル
ブミン複合体の内、最も酸敗し易い1)ヤツメウ
ナギ油−アルブミン(0.5:1)複合体、2)ヤ
ツメウナギ油−アルブミン複合体(1:1、アス
コルビン酸ステアリン酸エステル、ビタミンEを
ヤツメウナギ油に対し0.5%含む)を通気性を有
する瓶に入れて、40℃、湿度75%で30日間又は60
日間保存した後、前記と同様な方法で抽出し、そ
の過酸化物価、酸価、ヨウ素価及びケン価を下記
の方法により測定した。尚、無処理のヤツメウナ
ギ油を同一条件下30日間又は60日間保存したもの
を対照として用いた。その結果を第2表及び第3
表に示す。
過酸化物価(POV)の測定方法
前記脂肪油の抽出法により得られた脂肪油(以
下、試料油と称す)1gを200ml共栓フラスコに精
秤し、酢酸:四塩化炭素(3:2)を25ml加え、
さらに飽和ヨウ化カリウム水溶液0.5mlを加えて
2分間静かに振盪し、次いで50mlの水を加えて
0.01Nチオ硫酸ナトリウム試液で滴定する。
POV=A×F/T×10
A:0.01Nチオ硫酸ナトリウム試液(ml)
F:フアクター
T:試料油(g)
酸価の測定方法
試料油1gを250ml共栓フラスコに精秤しベンゼ
ン:エタノール(1:1)溶液100ml及びフエノ
ールフタレイン試液1乃至2滴を加えて、0.1N
水酸化ナトリウム・エタノール溶液で滴定する。
酸価=B×5.611×F/T
B: 0.1N水酸化ナトリウム・エタノール
(ml)
F:フアクター
T:試料油(g)
ヨウ素価の測定方法
試料油0.1乃至0.15gを500ml共栓フラスコに精
秤し、これに四塩化炭素10mlを加えて振盪する。
さらに三塩化ヨウ素試液を正確に25ml加え密栓し
て暗所に時々振盪しながら1時間放置する。次い
でヨウ化カリウム溶液20mlを加え、さらに水100
mlを加えて充分に振盪した後0.1Nチオ硫酸ナト
リウム液で滴定する。指示薬はデンプン試液1ml
を用いる。同条件で空試験を行う。
ヨウ素価=(A−B)×1.269/T
A: 空試験時の0.1Nチオ硫酸ナトリウム試
液量(ml)
B: 試料油の0.1Nチオ硫酸ナトリウム試液
量(ml)
T:試料油(g)
ケン価の測定方法
試料油2gを250mlの硬質平底フラスコに精秤
し、カセイカリアルコール溶液25ml(カセイカリ
約32gを同量の蒸留水に溶解し、アルコールを加
えて1とする)を加え還流冷却器を取り付けて
湯浴上で30分間加熱する(アルコールがわずかに
沸騰する程度)。この間フラスコを静かに揺り動
かしてケン化を促進する。
冷却後フエノールフタレインを指示薬として
0.5N塩酸で残りのカセイカリ量を滴定する。空
試験は材料を加えないで行う。
ケン価=(A−B)×28.05/T
A:空試験時の0.5N塩酸試液量(ml)
B:試料油の0.5N塩酸試液量(ml)
T:試料油(g)[Table] Furthermore, among the powdered fatty oil-albumin complexes obtained in the present invention, the most susceptible to rancidity are 1) lamprey oil-albumin (0.5:1) complex, 2) lamprey oil-albumin complex (1) :1.Pour ascorbic acid stearate (containing 0.5% of vitamin E in lamprey oil) in a breathable bottle and store at 40℃ and 75% humidity for 30 days or 60 days.
After being stored for a day, it was extracted in the same manner as above, and its peroxide value, acid value, iodine value, and saponyl value were measured by the following methods. In addition, untreated lamprey oil stored under the same conditions for 30 or 60 days was used as a control. The results are shown in Tables 2 and 3.
Shown in the table. Method for measuring peroxide value (POV) 1 g of fatty oil obtained by the above fatty oil extraction method (hereinafter referred to as sample oil) was accurately weighed into a 200 ml stoppered flask, and acetic acid: carbon tetrachloride (3:2) was added. Add 25ml of
Furthermore, add 0.5 ml of saturated potassium iodide aqueous solution and shake gently for 2 minutes, then add 50 ml of water.
Titrate with 0.01N sodium thiosulfate test solution. POV=A×F/T×10 A: 0.01N sodium thiosulfate test solution (ml) F: Factor T: Sample oil (g) Method for measuring acid value Accurately weigh 1 g of sample oil into a 250 ml stoppered flask, and benzene: ethanol (1:1) Add 100ml of solution and 1 to 2 drops of phenolphthalein test solution, and add 0.1N
Titrate with sodium hydroxide/ethanol solution. Acid value = B x 5.611 x F/T B: 0.1N sodium hydroxide/ethanol (ml) F: Factor T: Sample oil (g) Method for measuring iodine value Pour 0.1 to 0.15 g of sample oil into a 500 ml stoppered flask. Weigh, add 10 ml of carbon tetrachloride, and shake.
Add exactly 25 ml of iodine trichloride test solution, cap tightly, and leave in a dark place for 1 hour with occasional shaking. Then add 20ml of potassium iodide solution and add 100ml of water.
ml and shake thoroughly, then titrate with 0.1N sodium thiosulfate solution. The indicator is 1ml of starch test solution.
Use. Perform a blank test under the same conditions. Iodine value = (A-B) x 1.269/T A: Amount of 0.1N sodium thiosulfate test solution during blank test (ml) B: Amount of 0.1N sodium thiosulfate test solution of sample oil (ml) T: Sample oil (g) Measuring method for saponification number: Accurately weigh 2 g of sample oil into a 250 ml hard flat-bottomed flask, add 25 ml of caustic potash alcohol solution (about 32 g of caustic potash is dissolved in the same amount of distilled water, and add alcohol to make 1), and cool under reflux. Attach the container and heat on a hot water bath for 30 minutes (just enough to bring the alcohol to a slight boil). During this time, gently shake the flask to promote saponification. After cooling, use phenolphthalein as an indicator.
Titrate the remaining amount of caustic potash with 0.5N hydrochloric acid. A blank test is performed without adding any material. Ken number = (A-B) x 28.05/T A: Amount of 0.5N hydrochloric acid test solution during blank test (ml) B: Amount of 0.5N hydrochloric acid test solution of sample oil (ml) T: Sample oil (g)
【表】【table】
【表】
実施例 1
卵白アルブミン10gを100mlの水に溶解し、該
溶解液にヤツメウナギ油5gを加え室温で24時間
攪拌した。攪拌終了後該反応溶液にエタノール
100mlを加え、減圧乾燥することにより淡褐色粉
末状のヤツメウナギ油−卵白アルブミン複合体
14.9g(結合割合0.5:1)を得た。
実施例 2
卵白アルブミン1gを100mlの水に溶解し、該溶
解液にγ−リノレン酸5gを加え室温で24時間攪
拌した。攪拌終了後スプレイドライヤーを用いて
乾燥することにより白色粉末状のγ−リノレン酸
−卵白アルブミン複合体4.3g(結合割合5:1)
を得た。
実施例 3
卵白アルブミン2.5gを100mlの水に溶解し、該
溶解液にオリーブ油5.0gを加え室温で15分間高速
攪拌した。攪拌終了後、該反応溶液にエタノール
50mlを加えた後溶媒を留去し、次いで減圧乾燥す
ることにより淡黄白色粉末状のオリーブ油−卵白
アルブミン複合体7.4g(結合割合2:1)を得た。
実施例 4
卵白アルブミン5.0gを100mlの水に溶解したの
ち、月見草油3.0gを加え室温で15分間高速攪拌し
た。攪拌終了後、該反応溶液にエタノール50mlを
加え、減圧乾燥することにより淡黄白色粉末状の
月見草油−卵白アルブミン複合体7.9g(結合割合
0.6:1)を得た。
実施例 5
卵白アルブミン5gを100mlの水に溶解したの
ち、該溶解液にヤツメウナギ油5gにアスコルビ
ン酸ステアリン酸エステル・天然ビタミンE25mg
(1:5)を加えて攪拌したものを加え、窒素気
流中、氷冷下に2.5時間攪拌し均質化した。得ら
れた該水溶液をスプレードライヤーを用いてヤツ
メウナギ油−卵白アルブミン複合体9.8g(結合割
合1:1)を得た。[Table] Example 1 10 g of ovalbumin was dissolved in 100 ml of water, and 5 g of lamprey oil was added to the solution and stirred at room temperature for 24 hours. After stirring, add ethanol to the reaction solution.
Add 100ml and dry under reduced pressure to obtain light brown powdered lamprey oil-egg albumin complex.
14.9 g (binding ratio 0.5:1) was obtained. Example 2 1 g of ovalbumin was dissolved in 100 ml of water, and 5 g of γ-linolenic acid was added to the solution, followed by stirring at room temperature for 24 hours. After stirring, drying using a spray dryer yields 4.3 g of γ-linolenic acid-egg albumin complex in white powder form (binding ratio 5:1).
I got it. Example 3 2.5 g of ovalbumin was dissolved in 100 ml of water, 5.0 g of olive oil was added to the solution, and the mixture was stirred at high speed for 15 minutes at room temperature. After stirring, add ethanol to the reaction solution.
After adding 50 ml, the solvent was distilled off and then dried under reduced pressure to obtain 7.4 g of an olive oil-egg albumin complex (binding ratio 2:1) in the form of a pale yellowish white powder. Example 4 After dissolving 5.0 g of ovalbumin in 100 ml of water, 3.0 g of evening primrose oil was added and stirred at high speed for 15 minutes at room temperature. After stirring, 50 ml of ethanol was added to the reaction solution and dried under reduced pressure to obtain 7.9 g of evening primrose oil-ovalbumin complex (binding ratio) in the form of pale yellowish white powder.
0.6:1) was obtained. Example 5 After dissolving 5 g of egg albumin in 100 ml of water, 5 g of lamprey oil, 25 mg of ascorbic acid stearate, and natural vitamin E were added to the solution.
(1:5) was added and stirred, and the mixture was stirred for 2.5 hours under ice cooling in a nitrogen stream to homogenize. The obtained aqueous solution was used in a spray dryer to obtain 9.8 g of lamprey oil-ovalbumin complex (binding ratio 1:1).
Claims (1)
脂肪油−アルブミン複合体。 2 アルブミンが卵白アルブミンである特許請求
の範囲第1項記載の複合体。 3 液状脂肪油が炭素数6乃至24の飽和脂肪酸で
ある特許請求の範囲第1項記載の複合体。 4 液状脂肪油がパルミトオレイン酸、オレイン
酸、リノール酸、リノレン酸、エイコサペンタエ
ン酸又はドコサヘキサエン酸である特許請求の範
囲第1項記載の複合体。 5 液状脂肪油がヤツメウナギ油である特許請求
の範囲第1項記載の複合体。 6 アスコルビン酸又はそのエステル及びビタミ
ンEを安定剤として含有する特許請求の範囲第1
項乃至第5項のいずれか1項に記載の複合体。[Scope of Claims] 1. A powdered fatty oil-albumin complex in which liquid fatty oil is combined with albumin. 2. The complex according to claim 1, wherein the albumin is ovalbumin. 3. The complex according to claim 1, wherein the liquid fatty oil is a saturated fatty acid having 6 to 24 carbon atoms. 4. The complex according to claim 1, wherein the liquid fatty oil is palmitooleic acid, oleic acid, linoleic acid, linolenic acid, eicosapentaenoic acid or docosahexaenoic acid. 5. The complex according to claim 1, wherein the liquid fatty oil is lamprey oil. 6 Claim 1 containing ascorbic acid or its ester and vitamin E as a stabilizer
The complex according to any one of items 5 to 6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8111886 | 1986-04-10 | ||
JP61-81118 | 1986-04-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6344844A JPS6344844A (en) | 1988-02-25 |
JPH0567679B2 true JPH0567679B2 (en) | 1993-09-27 |
Family
ID=13737463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62084625A Granted JPS6344844A (en) | 1986-04-10 | 1987-04-08 | Powdery fat oil-albumin complex |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6344844A (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02218796A (en) * | 1988-10-28 | 1990-08-31 | Q P Corp | Fat and oil composition and composition of food or the like |
JPH02155990A (en) * | 1988-12-07 | 1990-06-15 | Asama Kasei Kk | Stabilized oil or fat powder and manufacture thereof |
JP3287081B2 (en) * | 1992-11-27 | 2002-05-27 | 株式会社ニフコ | Drawer unit |
-
1987
- 1987-04-08 JP JP62084625A patent/JPS6344844A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS6344844A (en) | 1988-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110301483A (en) | The purposes of fullerene compound and fullerene microcapsule powder and its preparation method and application | |
CA3121055C (en) | Preparation comprising a dispersion of phospholipids and fatty acid salts | |
WO2004048496A1 (en) | Composition containing organic substance having double bond with improved oxidation stability | |
ES2956766T3 (en) | Tablets with a high content of active ingredients of omega-3 fatty acid salts and amino acids | |
AU636582B2 (en) | Triglycerides, nutritional composition comprising such triglycerides, and use of the nutritional composition for nutrition | |
Qiu et al. | Biosafety evaluation of Nannochloropsis oculata and Schizochytrium sp. oils as novel human milk fat substitutes | |
JP2009530357A (en) | Association of a mixture of two or more cyclodextrins with an oily substance | |
KR910004346B1 (en) | Process for making powdered complex | |
JPH0567679B2 (en) | ||
JP2002539138A (en) | Solubilization of polyunsaturated fatty acids and their derivatives by forming inclusion complexes with gamma-cyclodextrin and use of said complexes in pharmaceutical, cosmetic or food compositions | |
JPH01153629A (en) | Anticancer agent | |
JPS60204739A (en) | Powder containing eicosapolyenoic acid based compound | |
JP2780383B2 (en) | Powdered fats and oils and method for producing the same | |
JPS6049747A (en) | Phospholipid composition | |
JP3640005B2 (en) | Soft capsule coating | |
JPH11253112A (en) | Protein-free healthy food | |
JPH0586395A (en) | Stabilization of fat and oil containing eicosapentaenoic acid and/or docosahexaenoic acid | |
JPS6277320A (en) | L-ascorbic acid pharmaceutical and production thereof | |
JP7367275B2 (en) | oily composition | |
JPH01290625A (en) | Cerebral function improver | |
KR102061932B1 (en) | Method for manufacturing fatty acid salt extracted from natural material, fatty acid salt manufactured by the same and formulation including the same | |
JP3550176B2 (en) | Tocopherol-enriched refined sesame oil, fat infusion containing it and oral preparation | |
JP2001288079A (en) | Specific carcinostatic agent and composition obtained by formulating the same | |
Orlova et al. | Improving the Quality of Medicinal Products by a Microencapsulation Method | |
KR20050036012A (en) | Phospholipid compositions containing poly unsaturated fatty acids and it's manufacturing process |